The current post-surgery standard of care for IDH-mutated low-grade gliomas, in patients classified as “high risk”, consists of a combined adjuvant chemo-radiotherapy regimen, associated with short- and long-term toxicity, but which guarantees a long period of clinical and radiological remission; patients classified as “low risk”, instead, do not receive adjuvant treatment and are subjected to periodic clinical and radiological observation (4, 5). The gene discussed is IDH1; the disease is central nervous system cancer.